Developing new antibiotic treatments, promoting responsible use, and ensuring access for all

 

‘Without harmonized and immediate action on a global scale, the world is heading towards a post-antibiotic era in which common infections could once again kill.’

Global Action Plan on Antimicrobial Resistance, World Health Organization, 2015

The mission of the Global Antibiotic Research and Development Partnership (GARDP) is to develop new antibiotic treatments addressing antimicrobial resistance and to promote their responsible use for optimal conservation, while ensuring equitable access for all in need. GARDP is being incubated by the Drugs for Neglected Diseases initiative (DNDi) in collaboration with the World Health Organization (WHO) and in support of the Global Action Plan for Antimicrobial Resistance.

A partnership model for product development based on the experience gained from the field of neglected diseases can provide an important element of the overall strategy for R&D in the field of antibiotics. Such a partnership can test new incentives that also contribute to conservation of and access to new antibiotic treatments. By doing so, it can provide an important alternative to the traditional market-driven pharmaceutical approach, by focusing on products that the pharmaceutical industry will likely not develop for lack of profitability.

Launched in May 2016, GARDP is now in its incubation, or start-up phase, hosted by DNDi. This means that until the end of 2017, GARDP will build up its team, establish a legal entity, and set out its long-term strategy and roadmap. In addition, GARDP aims to have at least two projects that address urgent global health needs ready for implementation by the end of 2016, and two more by the end of 2017. Visit the GARDP website

 

How does GARDP work?

GARDP works closely with all stakeholders in the field of antibiotic research and development (R&D) – including pharmaceutical and biotechnology companies, startups, other product development partnerships, academia, civil society, and health authorities – from countries of all income levels – to develop new antibiotic treatments.

GARDP:

  • addresses global public health and specific needs of low- and middle-income countries;
  • targets products that industry will likely not develop due to lack of profitability or other reasons;
  • pilots the use of alternative incentive models delinking cost of R&D from volume-based sales and prices of antibiotics, which support conservation of and access to new antibiotics; and
  • ensures that new antibiotics developed by GARDP are affordable to all in need.

Hosted by DNDi, the GARDP team is responsible for developing the GARDP business plan; fundraising; building the scientific strategy; setting up a scientific working group and steering committee; preparing for the creation of an independent entity; and building a product pipeline. GARDP’s governance is de facto embedded into DNDi’s governance structure during this start-up phase. WHO will provide support in priority setting, stewardship, and access; report back to its Member States; secure close collaboration with the AMR Secretariat, relevant WHO departments, the Essential Medicines List team, and the Global Health R&D Observatory; and provide other technical input where needed.